Related Experiment Video
Updated: Feb 11, 2026

Determining Basal Energy Expenditure and the Capacity of Thermogenic Adipocytes to Expend Energy in Obese Mice
Published on: November 11, 2021
Oxyntomodulin analogue increases energy expenditure via the glucagon receptor
1Division of Diabetes, Endocrinology and Metabolism, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom.
Abstract:
The gut hormone oxyntomodulin (OXM) causes weight loss by reducing appetite and increasing energy expenditure. Several analogues are being developed to treat obesity. Exactly how oxyntomodulin works, however, remains controversial. OXM can activate both glucagon and GLP-1 receptors but no specific receptor has been identified. It is thought that the anorectic effect occurs predominantly through GLP-1 receptor activation but, to date, it has not been formally confirmed which receptor is responsible for the increased energy expenditure. We developed OX-SR, a sustained-release OXM analogue. It produces a significant and sustained increase in energy expenditure in rats as measured by indirect calorimetry. We now show that this increase in energy expenditure occurs via activation of the glucagon receptor. Blockade of the GLP-1 receptor with Exendin 9-39 does not block the increase in oxygen consumption caused by OX-SR. However, when activity at the glucagon receptor is lost, there is no increase in energy expenditure. Glucagon receptor activity therefore appears to be essential for OX-SR's effects on energy expenditure. The development of future 'dual agonist' analogues will require careful balancing of GLP-1 and glucagon receptor activities to obtain optimal effects.
Insights
Oxyntomodulin (OXM) increases energy expenditure through glucagon receptor activation, not GLP-1 receptors. This finding is crucial for developing effective obesity treatments with dual-acting analogues.
Area of Science:
- Metabolism and Endocrinology
- Pharmacology
- Obesity Research
Background:
- Oxyntomodulin (OXM) is a gut hormone recognized for its potential in weight management by suppressing appetite and boosting energy expenditure.
- The precise mechanisms underlying OXM's physiological effects, particularly the receptor(s) mediating increased energy expenditure, remain incompletely understood.
- While OXM interacts with both glucagon and GLP-1 receptors, the specific receptor responsible for its thermogenic effects is debated.
Purpose of the Study:
- To investigate the specific receptor pathways responsible for the energy expenditure effects of the sustained-release oxyntomodulin analogue, OX-SR.
- To determine whether glucagon receptor or GLP-1 receptor activation is primarily responsible for OX-SR-induced increases in energy expenditure.
- To provide insights for the rational design of novel obesity therapeutics targeting OXM pathways.
Main Methods:
- Utilized indirect calorimetry in rats to measure energy expenditure following administration of OX-SR.
- Employed receptor blockade strategies, specifically using Exendin 9-39 to inhibit GLP-1 receptor activity.
- Assessed the impact of glucagon receptor antagonism on OX-SR-mediated energy expenditure changes.
Main Results:
- OX-SR administration led to a significant and sustained increase in energy expenditure in rats.
- Blocking the GLP-1 receptor with Exendin 9-39 did not attenuate the increase in oxygen consumption induced by OX-SR.
- Inhibition of glucagon receptor activity abolished the OX-SR-stimulated increase in energy expenditure, confirming its essential role.
Conclusions:
- Glucagon receptor activation is essential for the observed increase in energy expenditure mediated by the sustained-release oxyntomodulin analogue OX-SR.
- The anorectic effects of OXM may involve GLP-1 receptors, but its thermogenic effects are primarily mediated via glucagon receptors.
- Future development of dual-acting analogues for obesity treatment necessitates a careful balance of GLP-1 and glucagon receptor activities to optimize therapeutic outcomes.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Hypoglycemia and Glucagon
What is Energy?
Free Energy
Ionization Energy
Increasing Function

